venBio Partners
VC · San Francisco · United States
Stages
Investment region
Industries
Profile
venBio Partners is a venture capital firm based in San Francisco, founded in 2011 by Corey Goodman and Robert Adelman. The firm focuses on life sciences, specifically aiming to partner with industry leaders to develop game-changing medicines and technologies. The team includes experienced professionals like Corey Goodman, Aaron Royston, and Richard Gaster, who bring a wealth of knowledge in various scientific and investment disciplines. venBio distinguishes itself through a strong focus on unmet medical needs and a strategy aligned with potential acquisition partners from the outset. The firm invests in the life sciences sector, with an emphasis on novel therapeutics for unmet medical needs. Their venture funds comprise nearly $2 billion in committed capital. venBio's investment stages typically span Series A through late-stage opportunities. While based in North America, their geographic investment focus is global due to the nature of biotech innovation. Notable portfolio companies include Vicebio, a next-generation vaccine biotech acquired by Sanofi for $1.6 billion, and Candid Therapeutics, recognized as a 2025 Endpoints 11 Honoree. VenBio works closely with its portfolio to navigate clinical trial design, regulatory considerations, and overall development strategy.
担当者 (2)
| Name | Title | 電話 | ||
|---|---|---|---|---|
| Managing Partner | — | — | — | |
| Managing Partner | — | — | — |
Name, email and phone are partially hidden. Subscribe to see them in full.